Lentigen Corp.
This article was originally published in Start Up
Executive Summary
Lentigen has big plans for its HIV-1 based lentiviral vector technology. Short term, it plans to leverage its platform to become the leading provider of lentiviral vector research products and services to academic, government and biopharma scientists. These revenues will help cover the company's burn rate and fund future therapeutic product development programs.